Vysis gets licence for foetal cell analysis
This article was originally published in Clinica
Executive Summary
Roche Diagnostics has granted Vysis an exclusive licence to technology and intellectual property rights for genetic markers, which could allow for the unique identification of foetal cells in maternal blood. Once identified, Vysis' fluorescence in situ hybridisation technology can detect and analyse foetal cells for genetic abnormalities associated with mental retardation and birth defects, the company says.